VICTORIA (Completed)
A randomized parallel-group, placebo-controlled, double-blind, event-driven, multicenter pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator vericiguat (BAY 1021189) in patients with heart failure and reduced ejection fraction (HFrEF) -VerICiguaT glObal study in patients with HF and Reduced ejectIon frAction (VICTORIA)
- Medicine
- Vericiguat
- Population
- Heart failure
- Phase
- III
- Starting year
- 2016
- More information
- ClinicalTrials.gov